TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28408121

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV4)
Number of subjects: 1511

Group type: COMPARATOR
Intervention: Inactivated influenza vaccine (IIV)
Number of subjects: 1511
Study: 28408140

Group type: EXPERIMENTAL
Intervention: Menopause (pre-menopausal women)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Aging (post-menopausal women)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (age-matched men for pre-menopausal women)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (age-matched men for post-menopausal women)
Number of subjects: 76
Study: 28408363

Group type: EXPERIMENTAL
Intervention: WittyFit intervention including baseline health profiling, individualized feedback, support for behavioral change, and evaluation of changes over time.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WittyFit intervention for middle managers including anonymous feedback on employee problems.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WittyFit intervention for executive managers providing indicators by division, location, department, age, seniority, gender, and occupational position.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WittyFit intervention incorporating morbidity and well-being data.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: WittyFit intervention with the ability to include mortality as an outcome.
Number of subjects: 0
Study: 28408434

Group type: EXPERIMENTAL
Intervention: Uric acid lowering intervention, details not specified
Number of subjects: 0
Study: 28408462

Group type: EXPERIMENTAL
Intervention: CD19 CAR T cells of defined formulation and dose
Number of subjects: 45
Study: 28408615

Group type: EXPERIMENTAL
Intervention: Bortezomib, cyclophosphamide, and rituximab
Number of subjects: 21
Study: 28409004

Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 48

Group type: COMPARATOR
Intervention: Not applicable (no intervention)
Number of subjects: 48
Study: 28409005

Group type: EXPERIMENTAL
Intervention: HIV-COPD cases
Number of subjects: 38
Study: 28409297

Group type: EXPERIMENTAL
Intervention: SLCO1A2 -189_-188InsA genotype (n = 17)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SLCO1A2 -/- genotype (n = 13)
Number of subjects: 30
Study: 28409328

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 63
Study: 28409685

Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography during Recruitment Maneuvers
Number of subjects: 0
Study: 28409730

Group type: EXPERIMENTAL
Intervention: Activa PC+S system (Medtronic Inc.)
Number of subjects: 5
Study: 28410181

Group type: EXPERIMENTAL
Intervention: Weight loss intervention (6-month duration) via group conference calls
Number of subjects: 37

Group type: COMPARATOR
Intervention: Weight loss maintenance phase (months 6-18) with continued group calls or mailed newsletters
Number of subjects: 37
Study: 28410187

Group type: EXPERIMENTAL
Intervention: Provider-initiated SCP
Number of subjects: 41

Group type: COMPARATOR
Intervention: Patient-initiated SCP
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Both arms (Provider-initiated and Patient-initiated)
Number of subjects: 41
Study: 28410341

Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) 400 mg every 4 weeks up to 7 years
Number of subjects: 595

Group type: EXPERIMENTAL
Intervention: Transient CZP-ADAb-positive
Number of subjects: 595

Group type: COMPARATOR
Intervention: CZP-ADAb-negative
Number of subjects: 595
Study: 28410572

Group type: EXPERIMENTAL
Intervention: Internal fixation with prophylactic antibiotics (intra-operative: 92.1%, post-operative: 96.8%)
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Internal fixation with antibiotics prescribed for an average of 8.3 days for closed fractures and 9.1 days for open fractures
Number of subjects: 787

Group type: EXPERIMENTAL
Intervention: Internal fixation with infections present
Number of subjects: 787
Study: 28410583

Group type: EXPERIMENTAL
Intervention: Virtual reality task (coincidence-timing task)
Number of subjects: 20
Study: 28410813

Group type: EXPERIMENTAL
Intervention: PCV13 vaccination
Number of subjects: 84496
Study: 28410816

Group type: EXPERIMENTAL
Intervention: Prevnar13 vaccination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 10
Study: 28410911

Group type: COMPARATOR
Intervention: nccRCC
Number of subjects: 4527

Group type: COMPARATOR
Intervention: nccRCC (intermediate- and poor-risk)
Number of subjects: 4527

Group type: COMPARATOR
Intervention: nccRCC (favorable risk)
Number of subjects: 4527

Group type: COMPARATOR
Intervention: nccRCC (vascular endothelial growth factor-targeted therapy)
Number of subjects: 4527

Group type: COMPARATOR
Intervention: nccRCC (mammalian target of rapamycin inhibitors)
Number of subjects: 4527
Study: 28411249

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 30
Study: 28411261

Group type: EXPERIMENTAL
Intervention: Cardiovascular MRI (cvMRI)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Transesophageal echocardiography (TEE)
Number of subjects: 103
Study: 28411282

Group type: EXPERIMENTAL
Intervention: Presence of copy-number alterations (CNAs)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Presence of CNAs in standard-risk group
Number of subjects: 446
Study: 28411313

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Ad libitum buffet meal
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Picture display test
Number of subjects: 41
Study: 28412293

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir (300mg glecaprevir plus 120mg pibrentasvir) for 8 weeks in genotype 1-, 2-, or 3-infected patients
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir for 12 weeks
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir for 8 weeks
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Glecaprevir plus pibrentasvir
Number of subjects: 449
Study: 28413427

Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with TIV
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine (adjuvanted)
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: RSV F nanoparticle vaccine co-administered with TIV
Number of subjects: 220

Group type: COMPARATOR
Intervention: TIV
Number of subjects: 220
Study: 28413832

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 28414029

Group type: EXPERIMENTAL
Intervention: CAPTURE-S with selective use of PEF
Number of subjects: 30
Study: 28414819

Group type: EXPERIMENTAL
Intervention: HbA1c
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: PG
Number of subjects: 2233

Group type: EXPERIMENTAL
Intervention: FPG
Number of subjects: 2233

Group type: COMPARATOR
Intervention: CAVI and baPWV
Number of subjects: 2233
Study: 28414894

Group type: EXPERIMENTAL
Intervention: BEAT Cancer physical activity intervention
Number of subjects: 0
Study: 28415102

Group type: EXPERIMENTAL
Intervention: Fetuin-A level ≤0.53 g/L
Number of subjects: 296

Group type: COMPARATOR
Intervention: Fetuin-A level >0.53 g/L
Number of subjects: 296
Study: 28415993

Group type: EXPERIMENTAL
Intervention: Moving To Business (MTB) intervention
Number of subjects: 396
Study: 28416015

Group type: EXPERIMENTAL
Intervention: Augmentation therapy (AT)
Number of subjects: 2180

Group type: COMPARATOR
Intervention: No augmentation therapy (AT)
Number of subjects: 2180

Group type: COMPARATOR
Intervention: COPD patients without AATD
Number of subjects: 2180
Study: 28416221

Group type: EXPERIMENTAL
Intervention: Ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus dasabuvir 250 mg for 8 weeks
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Ombitasvir, paritaprevir, and ritonavir, plus dasabuvir, without ribavirin for 8 weeks
Number of subjects: 166
Study: 28416496

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention including a 3-week residential programme combining high exercise volume (15-20 hours/week), restrictive diet (-500 kcal/day), and education.
Number of subjects: 29
Study: 28416559

Group type: EXPERIMENTAL
Intervention: Nitroglycerin-based catheter lock solution (15 or 30 μg/ml of nitroglycerin in combination with 4% sodium citrate and 22% ethanol)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (saline or heparin flush)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Institutional rate
Number of subjects: 60
Study: 28416813

Group type: EXPERIMENTAL
Intervention: Estradiol secretion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Brain-derived neurotrophic factor (BDNF) Val
Number of subjects: 0
Study: 28417002

Group type: EXPERIMENTAL
Intervention: Anorexia Nervosa Stages of Change Questionnaire (ANSOCQ)
Number of subjects: 0
Study: 28417284

Group type: EXPERIMENTAL
Intervention: Voxtalisib 70 mg QD
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Voxtalisib 50 mg BID
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Voxtalisib 60 mg QD (MTD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Voxtalisib 40 mg BID (MTD)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Voxtalisib (all doses)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Voxtalisib with food
Number of subjects: 49
Study: 28417296

Group type: EXPERIMENTAL
Intervention: DPP4 inhibitors (saxagliptin)
Number of subjects: 0

Group type: COMPARATOR
Intervention: DPP4 inhibitors
Number of subjects: 0
Study: 28417532

Group type: EXPERIMENTAL
Intervention: Insulin-naïve T2D patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin-treated T2D patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Type 1 diabetes patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All populations
Number of subjects: 0
Study: 28419213

Group type: EXPERIMENTAL
Intervention: CMV PCR in saliva
Number of subjects: 11715

Group type: EXPERIMENTAL
Intervention: Primary maternal infection
Number of subjects: 11715

Group type: EXPERIMENTAL
Intervention: Nonprimary maternal infection
Number of subjects: 11715

Group type: EXPERIMENTAL
Intervention: Seronegative women before pregnancy
Number of subjects: 11715
Study: 28419237

Group type: EXPERIMENTAL
Intervention: FAT score ≥2
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Standard quantification method for scAT fibrosis
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: FAT score interobserver agreement
Number of subjects: 183
Study: 28419383

Group type: EXPERIMENTAL
Intervention: OSA
Number of subjects: 549

Group type: EXPERIMENTAL
Intervention: ACS
Number of subjects: 549

Group type: COMPARATOR
Intervention: Control
Number of subjects: 549
Study: 28420281

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for STEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for NSTEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) during hospitalization for UA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for STEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for NSTEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT) at discharge for UA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for STEMI patients managed by PCI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for STEMI patients conservatively treated
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for NSTEMI patients managed by PCI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: DAPT at 12 months for NSTEMI patients conservatively treated
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 1 year for STEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 2 years for STEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 1 year for NSTEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 2 years for NSTEMI
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 12 months for UA
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Cumulative incidence of all-cause mortality at 24 months for UA
Number of subjects: 600
Study: 28420280

Group type: EXPERIMENTAL
Intervention: Budesonide 9 mg or 6 mg once daily for 8 weeks (induction study)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg once daily for 12 weeks (maintenance study)
Number of subjects: 108
Study: 28420329

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced US using perfluorobutane
Number of subjects: 523

Group type: COMPARATOR
Intervention: Conventional B-mode US
Number of subjects: 523
Study: 28420362

Group type: EXPERIMENTAL
Intervention: Closed-loop, allostatic neurotechnology
Number of subjects: 19
Study: 28420419

Group type: EXPERIMENTAL
Intervention: Building Your New Normal program (automated telephone symptom management intervention)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Usual care enhanced with a non-tailored newsletter about symptom management
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Building Your New Normal program
Number of subjects: 600
Study: 28420429

Group type: EXPERIMENTAL
Intervention: DEPTOR knockdown in H929 and MM1S cell lines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of DEPTOR protein expression in myeloma patients
Number of subjects: 0
Study: 28420664

Group type: EXPERIMENTAL
Intervention: Intravenous iron administration according to hospital's preoperative pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 28420721

Group type: EXPERIMENTAL
Intervention: Fenretinide delivered intravenously
Number of subjects: 0
Study: 28421334

Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for at least 8 weeks
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Therapeutic drug monitoring
Number of subjects: 889
Study: 28421634

Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Number of subjects: 7
Study: 28422025

Group type: EXPERIMENTAL
Intervention: Prolonged glucocorticoid treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 28422442

Group type: EXPERIMENTAL
Intervention: Subgenotype C1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subgenotype B2 and C2
Number of subjects: 0
Study: 28422536

Group type: EXPERIMENTAL
Intervention: Self-monitoring
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Group/commercial support
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Other behavioral strategies
Number of subjects: 214
Study: 28422631

Group type: EXPERIMENTAL
Intervention: Functional assessments
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Virtual reality assessment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Paper-and-pencil assessments
Number of subjects: 12
Study: 28422751

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine (DC vaccine) injected intradermally in high doses over 2 years
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Dendritic cell vaccine (DC vaccine)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ipilimumab treatment
Number of subjects: 53
Study: 28422758

Group type: EXPERIMENTAL
Intervention: Regorafenib 80 mg daily plus cetuximab 200 mg/m2 loading dose, followed by 150 mg/m2 every week
Number of subjects: 27
Study: 28422836

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 30
Study: 28423296

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 1: day 14 to 6 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 2: day 14 to 3 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (cohort 3: day 1 to 6 months)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy (combined cohorts)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Historical cohort (no eltrombopag)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Eltrombopag plus standard immunosuppressive therapy
Number of subjects: 92
Study: 28424071

Group type: EXPERIMENTAL
Intervention: Imatinib (400 mg per day)
Number of subjects: 27
Study: 28424085

Group type: EXPERIMENTAL
Intervention: Combination therapy with antibiotics
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less drug pressure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitoring bacterial population dynamics
Number of subjects: 0
Study: 28424092

Group type: EXPERIMENTAL
Intervention: High frequency of fish food consumption
Number of subjects: 1092

Group type: COMPARATOR
Intervention: Low frequency of fish food consumption
Number of subjects: 1092
Study: 28424162

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg every 3 weeks)
Number of subjects: 25
Study: 28424891

Group type: EXPERIMENTAL
Intervention: Selumetinib plus Erlotinib (100 mg QD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Selumetinib plus Temsirolimus (25 mg once weekly)
Number of subjects: 80
Study: 28424889

Group type: EXPERIMENTAL
Intervention: Biweekly docetaxel with capecitabine
Number of subjects: 53
Study: 28425349

Group type: EXPERIMENTAL
Intervention: DWI-FLAIR mismatch
Number of subjects: 699

Group type: COMPARATOR
Intervention: No DWI-FLAIR mismatch
Number of subjects: 699
Study: 28425755

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration with percutaneous coronary intervention
Number of subjects: 1641

Group type: COMPARATOR
Intervention: Percutaneous coronary intervention alone
Number of subjects: 1641
Study: 28426120

Group type: EXPERIMENTAL
Intervention: Olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity.
Number of subjects: 30
Study: 28426811

Group type: EXPERIMENTAL
Intervention: Oral azithromycin (if PCT <0.5 ng/ml)
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Levofloxacin (if PCT ≥0.5 ng/ml)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Historical standard-of-care control group
Number of subjects: 253
Study: 28427285

Group type: EXPERIMENTAL
Intervention: Combined estradiol/progesterone
Number of subjects: 22

Group type: COMPARATOR
Intervention: Leuprolide (GnRH agonist)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Second and third months of estradiol/progesterone
Number of subjects: 22
Study: 28427380

Group type: EXPERIMENTAL
Intervention: Stepping Stones and Creating Futures intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 28427434

Group type: EXPERIMENTAL
Intervention: AdCD40L gene therapy
Number of subjects: 15
Study: 28427585

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 0
Study: 28427598

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)-based area oversizing
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: Computed tomography (CT)-based perimeter oversizing
Number of subjects: 835

Group type: EXPERIMENTAL
Intervention: SAPIEN 3 transcatheter heart valve (THV) implantation
Number of subjects: 835
Study: 28427826

Group type: COMPARATOR
Intervention: Suvorexant 30 mg (N=319)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Suvorexant 15 mg (N=202)
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo (N=469)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Suvorexant 15 mg
Number of subjects: 627

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 627
Study: 28428158

Group type: EXPERIMENTAL
Intervention: Mobile health intervention (smartphone app) for medication and symptom management
Number of subjects: 0
Study: 28428165

Group type: EXPERIMENTAL
Intervention: mHealth intervention (DREAM-GLOBAL) for hypertension management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mHealth intervention (DREAM-GLOBAL)
Number of subjects: 0
Study: 28428183

Group type: EXPERIMENTAL
Intervention: Non-cephalic presentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple births
Number of subjects: 0

Group type: COMPARATOR
Intervention: Singleton births
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cephalic presentation
Number of subjects: 0
Study: 28428225

Group type: EXPERIMENTAL
Intervention: Empagliflozin treatment for 2 days
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Empagliflozin treatment for 14 days
Number of subjects: 30
Study: 28428322

Group type: EXPERIMENTAL
Intervention: Continuous Subcutaneous Insulin Infusion (CSII)
Number of subjects: 590

Group type: COMPARATOR
Intervention: Multiple Daily Insulin Injections (MDI)
Number of subjects: 590
Study: 28428348

Group type: EXPERIMENTAL
Intervention: ADAPT (Direct Aspiration First Pass Technique)
Number of subjects: 347
Study: 28428882

Group type: EXPERIMENTAL
Intervention: Immunotherapy treated mice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients undergoing systemic high dose IL-2
Number of subjects: 0
Study: 28428884

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg twice daily and ipilimumab 3 mg/kg every 3 weeks
Number of subjects: 35
Study: 28429083

Group type: EXPERIMENTAL
Intervention: Fully implantable treprostinil infusion pump
Number of subjects: 30
Study: 28429860

Group type: EXPERIMENTAL
Intervention: Lixisenatide with biguanide
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lixisenatide with thiazolidinedione
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lixisenatide with alpha-glucosidase
Number of subjects: 294

Group type: EXPERIMENTAL
Intervention: Lixisenatide with glinide
Number of subjects: 294
Study: 28431167

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 87